The collaboration will give users of the Science Exchange access to RNA silencing products and gene-editing approaches, which can be used to shorten the time of genetic research and drug development.
Speaking to Gursatya Singh, scientific content and marketing director for Science Exchange, he said: “Most conventional technologies for elucidating gene function have key limitations that lead to longer discovery and development times. Offering instant access to AUM’s unique services can help scientists shorten the drug R&D cycle.”
AUM’s products utilize its FANA technology, which is composed of antisense oligonucleotide (AON) chemistries that can be used for targeting different types of RNA.
“A key advantage of FANA ASO technology is its ability to be self-delivered to the target genetic material without the use of delivery reagents or formulations,” said Singh.
This type of technology is particularly useful for genetic research on “difficult-to-transect” primary cells, and can be used in various types of studies through different methods of administration. It is also an alternative to CRISPR, a popular gene-editing tool.
This collaboration is all about cutting down costs and time, according to Singh: “Access to this technology can save significant time, money, and resources for the biomedical community.”